COMy 2024 | Quadruplet induction therapy in newly diagnosed high-risk myeloma
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses clinical trials on quadruplet induction therapy for newly diagnosed high-risk multiple myeloma. He highlights the Phase II IFM 2018-04 trial (NCT03606577), which tests the combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), and mentions the UK Myeloma Group’s investigation into adding cyclophosphamide to this regimen. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda.
Consulting: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
Speaker: Amgen, BMS, Janssen, Sanofi.
